ENDPOINTS

Bluebird gets new M&A bid, seeking to top private equity offer

Bluebird gets new M&A bid, seeking to top private equit...

Mar 28, 2025 0

A rival group is seeking to buy cell therapy biotech bluebird bio, in an effort ...

Amgen loses challenge to Colorado drug review board

Amgen loses challenge to Colorado drug review board

Mar 28, 2025 0

A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affo...

FDA approves Sanofi's RNAi drug for hemophilia A and B

FDA approves Sanofi's RNAi drug for hemophilia A and B

Mar 28, 2025 0

The FDA on Friday said it approved a new RNAi-based hemophilia treatment from Sa...

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

At long last, Novartis’ radiopharma drug Pluvicto gets ...

Mar 28, 2025 0

Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly antic...

J&J wins patent feud against Viatris over schizophrenia drug

J&J wins patent feud against Viatris over schizophrenia...

Mar 28, 2025 0

Johnson & Johnson scored an appeals court win in its bid to block generic compet...

CHMP acts on Opdivo, Tevimbra, Xoanacyl, Kisunla and others

CHMP acts on Opdivo, Tevimbra, Xoanacyl, Kisunla and ot...

Mar 28, 2025 0

Bristol Myers Squibb, BeiGene, AstraZeneca and Pfizer secured European backing f...

Milestone's shares dive after FDA again rejects drug for abnormal heart rhythm

Milestone's shares dive after FDA again rejects drug fo...

Mar 28, 2025 0

Milestone Pharmaceuticals’ nasal spray failed for a second time to secure US app...

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

DBV’s financing for peanut allergy patch; Eisai divests...

Mar 28, 2025 0

Plus, news about Palatin, Spero and BioAtla: DBV Technologies’ $306M financi...

European regulator rejects Lilly's Alzheimer’s drug over side effects

European regulator rejects Lilly's Alzheimer’s drug ove...

Mar 28, 2025 0

Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European...

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

BioNTech details promising mid-stage data for its PD-L1...

Mar 28, 2025 0

BioNTech has highly encouraging survival data for its bispecific antibody combin...

Novo makes oral obesity drug partnership with Lexicon worth up to $1B

Novo makes oral obesity drug partnership with Lexicon w...

Mar 28, 2025 0

Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday...

On the heels of staff cuts, CRISPR Therapeutics COO departs; Changes galore at Bicycle

On the heels of staff cuts, CRISPR Therapeutics COO dep...

Mar 28, 2025 0

→ After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the...

Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrin

Before Alumis went public via IPO, it tried doing a rev...

Mar 28, 2025 0

Last month's all-stock merger proposal between Alumis and Acelyrin wasn't the fi...

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Merck KGaA pays Abbisko $85M for full commercial rights...

Mar 28, 2025 0

Merck KGaA is spending $85 million to tap global commercialization rights to pim...

FDA’s policy, communications staff likely to be among agency’s 3,500 staff cuts

FDA’s policy, communications staff likely to be among a...

Mar 27, 2025 0

HHS’ plans to eliminate almost 20% of the FDA’s staff will likely take a major t...

Merck details injectable Keytruda data as it awaits FDA decision

Merck details injectable Keytruda data as it awaits FDA...

Mar 27, 2025 0

Merck shared Phase 3 data showing that an injectable version of its blockbuster ...

12
13
14
15
16

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.